Esperion Therapeutics/$ESPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Esperion Therapeutics
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Ticker
$ESPR
Sector
Primary listing
Employees
304
Headquarters
Website
ESPR Metrics
BasicAdvanced
$446M
-
-$0.53
0.82
-
Price and volume
Market cap
$446M
Beta
0.82
52-week high
$3.39
52-week low
$0.69
Average daily volume
5.8M
Financial strength
Current ratio
1.147
Quick ratio
0.649
Long term debt to equity
-109.424
Total debt to equity
-137.985
Interest coverage (TTM)
-0.39%
Profitability
EBITDA (TTM)
-27.408
Gross margin (TTM)
46.23%
Net profit margin (TTM)
-38.80%
Operating margin (TTM)
-10.26%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
-6.34%
Return on equity (TTM)
26.75%
Valuation
Price to revenue (TTM)
1.616
Price to book
-1.02
Price to tangible book (TTM)
-1.02
Price to free cash flow (TTM)
-3.481
Free cash flow yield (TTM)
-28.73%
Free cash flow per share (TTM)
-0.635
Growth
Revenue change (TTM)
-3.48%
Earnings per share change (TTM)
-21.55%
3-year revenue growth (CAGR)
58.38%
3-year earnings per share growth (CAGR)
-54.12%
10-year earnings per share growth (CAGR)
-13.33%
What the Analysts think about ESPR
Analyst ratings (Buy, Hold, Sell) for Esperion Therapeutics stock.
ESPR Financial Performance
Revenues and expenses
ESPR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Esperion Therapeutics stock?
Esperion Therapeutics (ESPR) has a market cap of $446M as of August 29, 2025.
What is the P/E ratio for Esperion Therapeutics stock?
The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of August 29, 2025.
Does Esperion Therapeutics stock pay dividends?
No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of August 29, 2025.
When is the next Esperion Therapeutics dividend payment date?
Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Esperion Therapeutics?
Esperion Therapeutics (ESPR) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.